Oviductus Ranae protein hydrolyzate prevents menopausal osteoporosis by regulating TGFβ/BMP2 signaling
- 44 Downloads
It is known that menopausal osteoporosis (MOP) is the most typical form of osteoporosis, which is characterized by low bone mass and microstructure damage of the bone tissue, leading to increased bone fragility and risk of fracture. This study aimed to evaluate the protective effects of Oviductus Ranae protein hydrolyzate (ORPH) on the MOP in vivo.
Osteoporosis model was induced by ovariectomy, treated with ORPH 150 or 75 mg kg−1. Body weight and bone mineral density (BMD) of rats were measured at the beginning and the end of the experiment, and femoral maximum load was determined immediately after killing. The expression levels of alkaline phosphatase (ALP), Smad4, tartrate acid phosphatase (TRAP), BMP2, Runx2, CPB, ColI and osteocalcin were examined by RT-PCR or western-blotting. HE staining was used to observe the pathological changes in the femurs. Immunohistochemistry was used to detect the expression of ALP and BMP2. All data were analyzed by SPSS 13.0.
The results revealed that ORPH had no effect on the weight of normal and osteoporotic rats. ORPH could significantly improve the femur BMD and increase the maximum load of the osteoporotic rats. ORPH could significantly upregulate the expression level of bone formation makers, ALP, osteocalcin, ColI, and Runx2, and downregulate the expression level of bone resorption marker, TRAP. In the ORPH group, the expression levels of BMP2, Smad4, and CPB of key proteins in the TGFβ/BMP2 signaling pathway were significantly upregulated. In addition, immunohistochemistry showed that ALP and BMP2 expression in femurs of the ORPH group was stranger. H&E staining showed that ORPH (150 mg kg−1) significantly increased the thickness of trabeculae and decreased fracture risk.
Collectively, ORPH plays a role in the prevention and treatment of osteoporosis, which may be a potential anti-osteoporosis drug.
KeywordsORPH Menopausal osteoporosis TGFβ/BMP2 BMD ALP
This work was funded by Jilin Province Traditional Chinese Medicine Administration and Jilin Province Department of Education.
XL, XQ and NL conceived and designed the study. XL, XS, QY, and XS performed the experiments. YL provided the Oviductus Ranae. XL wrote the paper. DH, YL, XH, PY and XQ reviewed and edited the manuscript. All authors read and approved the manuscript.
This study was funded by the Jilin Province Traditional Chinese Medicine Science and Technology Project (2017002, 2018024); the Jilin Provincial Department of Education Science Research Project (JJKH20181266KJ); the Jilin province science and technology backbone training project for health and hygiene (2018Q043).
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
- 1.National Pharmacopoeia Committee (2010) Pharmacopoeia of People’s Republic of China, Part 1. Chinese Medical Science and Technology Press, Beijing, p 239Google Scholar
- 2.Mousavi A, Nadjar Araabi B, Nili Ahmadabadi M (2014) Context transfer in reinforcement learning using action-value functions. Comput Intell Neurosci 14:428–433Google Scholar
- 5.Liang L, Zhang XH, Zhou Y, Huang YJ, Deng HZ (2008) Protective effect of Oviductus Ranae capsules on the reproductive organs of aged mice. Nan Fang Yi Ke Da Xue Xue Bao 28:982–985Google Scholar
- 6.Du X, Xu S, Wang W (1998) Research progress on deglycosylation of mucin glycoprotein. Nat Prod Res Dev 04:94–98Google Scholar
- 14.Samir SM, Malek HA (2014) Effect of cannabinoid receptors 1 modulation on osteoporosis in a rat model of different ages. J Physiol Pharmacol 65:687–694Google Scholar
- 22.Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, Stamp GW, Beddington RS, Mundlos S, Olsen BR, Selby PB, Owen MJ (1997) Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89:765–771CrossRefGoogle Scholar
- 31.Kanzler B, Foreman RK, Labosky PA, Mallo M (2000) BMP signaling is essential for development of skeletogenic and neurogenic cranial neural crest. Development 127:1095–1104Google Scholar
- 33.Thies RS, Bauduy M, Ashton BA, Kurtzberg L, Wozney JM, Rosen V (1992) Recombinant human bone morphogenetic protein-2 induces osteoblastic differentiation in W-20-17 stromal cells. Endocrinology 130:1318–1324Google Scholar
- 34.Zhang H, Bradley A (1996) Mice deficient for BMP2 are nonviable and have defects in amnion/chorion and cardiac development. Development 122:2977–2986Google Scholar